Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2016-11-04 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: Fresenius SE & Co. KGaA english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS. The document details the transaction (Acquisition) by a specific individual (Dr. Gerd Krick) who is a Member of the administrative or supervisory body.
2016-11-04 English
Fresenius Factsheet Q3 2016
Fund Information / Factsheet Classification · 98% confidence The document is explicitly titled "Factsheet Q3/2016" and contains key financial figures, segment breakdowns, balance sheet data, and outlook targets for the first three quarters of 2016, comparing them to Q1-3/2015 and FY/2015. This structure—a concise summary of key performance indicators for a specific interim period—aligns perfectly with the definition of a Fund Information / Factsheet (FS). It is not a comprehensive regulatory report like a 10-K or IR, nor is it an announcement of a report (RPA).
2016-11-03 English
Fresenius Factsheet Q3 2016
Fund Information / Factsheet Classification · 98% confidence The document is explicitly titled "# Factsheet Q3 / 2016" and contains key financial metrics (Umsatz, EBIT, Bilanzsumme) for Q1-3/2016 compared to Q1-3/2015 and FY/2015. It also includes segment performance, stock information, and a financial calendar. This structure—a concise summary of key figures and operational highlights for a specific interim period (Q3/9 months)—is characteristic of a Fund Information / Factsheet document, which summarizes essential data points for investors, rather than a comprehensive regulatory report like an Annual Report (10-K) or an Interim Report (IR). The definition for Fund Information / Factsheet (FS) is 'Brief (1-2 page) summary of key company facts, financials, and market info,' which aligns perfectly with this document's content and format.
2016-11-03 German
Q3 statement / Q3 financial report 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Financial Report' for the Fresenius Group covering the 1st to 3rd quarters of 2016. It contains comprehensive financial statements, including consolidated statements of income, cash flows, and segment reporting, as well as a detailed management report. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim / Quarterly Report (IR). 9M 2016
2016-11-01 German
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It announces the 'Publication of total number of voting rights' and details a 'Conditional capital increase' effective on 31.10.2016, providing the new total number of voting rights (546,948,131). This type of mandatory disclosure regarding changes in voting rights or capital structure, especially when published via a regulatory service like DGAP, fits best under the category related to capital structure changes or mandatory regulatory disclosures. Since there is no specific code for 'Total Voting Rights Announcement', I must evaluate the closest fit. It is not an ER, IR, 10-K, or AGM-R. It relates to capital structure changes ('Conditional capital increase'), making 'CAP' (Capital/Financing Update) a possibility, but the core function is reporting the total voting rights count, which is a specific regulatory notification. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for specific, mandatory regulatory announcements that don't fit the primary financial report codes (10-K, IR, ER) or specific corporate actions like DIV or DIRS. However, since it explicitly details a capital measure ('Conditional capital increase'), 'CAP' is a strong candidate. Let's re-examine the definitions. 'CAP' is for fundraising/financing activities or capital structure changes. A change in total voting rights due to a capital increase directly impacts the capital structure. Therefore, 'CAP' is more specific than the general 'RNS'.
2016-10-31 English
Conference Call Q3 2016
Call Transcript Classification · 98% confidence The document is titled "Conference Call – Q3/2016 Results" and contains detailed financial tables, operational highlights, outlook updates, and segment-specific performance metrics for the third quarter of 2016 (Q3/2016). It includes sections like 'Fresenius Group: Q3/2016 Key Financials', 'Fresenius Kabi', 'Fresenius Helios', and 'Fresenius Vamed' EBIT and sales data. This structure is characteristic of an Earnings Release (ER) which provides initial key highlights, or potentially a Call Transcript (CT) if it were the full transcript. Since the text is highly structured with financial tables and performance summaries, and it is explicitly labeled as a 'Conference Call' document presenting 'Results', it strongly aligns with the content typically presented during an earnings call. Given the options, 'Call Transcript' (CT) is the most appropriate classification for the content of a conference call detailing quarterly results, even if the Q&A section is not present in this excerpt, as the document format is clearly derived from the presentation materials used during such a call. However, if the primary purpose is the *release* of the results summary, ER is also plausible. Since the text is extensive and structured like a presentation used in a call, CT is a strong candidate. Reviewing the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. CT is 'Full text transcript of company conference calls (like earnings calls with Q&A)'. This looks like the presentation slides used in the call, which often accompanies the ER or forms the basis of the CT. Given the depth of financial detail presented in a slide-like format, it is more than just 'key highlights' (ER), but it is not explicitly a 'transcript' (CT). In many databases, the presentation material accompanying an earnings call is classified as the Earnings Release (ER) or Investor Presentation (IP). Since it details Q3 results and outlook, ER is a very strong fit for the *information* being conveyed. Given the title 'Conference Call – Q3/2016 Results', and the content being the results presentation itself, ER (Earnings Release) is the most fitting category for the release of these period results.
2016-10-27 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.